+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Osteoporosis Epidemiology Forecast to 2028

  • ID: 4871927
  • Report
  • December 2019
  • Region: Global
  • 100 pages
  • DelveInsight
1 of 2
‘Osteoporosis - Epidemiology Forecast to 2028' report delivers an in - depth understanding of the disease, historical, and forecasted epidemiology of Osteoporosis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017 - 2028

Osteoporosis Epidemiology

The Osteoporosis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Osteoporosis are studied through all possible division to give a better understanding of the Disease scenario in the 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Osteoporosis Epidemiology Segmentation

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by:
  • Prevalence of Osteoporosis
  • Diagnosed Prevalent Population of Osteoporosis
  • Gender - specific Prevalence of Osteoporosis
  • Prevalence of Primary Osteoporosis
  • Prevalence of Secondary Osteoporosis
  • Incidence of Osteoporotic Fractures
  • Osteoporosis - related comorbidities
According to this research, the total diagnosed prevalent population of Osteoporosis in the seven major markets were 28,097,783 cases in 2017. Moreover, the total diagnosed prevalent population of Osteoporosis in the US were 6,380,754 cases in 2017.

Report Scope
  • The report covers the detailed overview of Osteoporosis explaining its causes, symptoms, pathophysiology, diagnostic biomarkers, differential diagnosis, diagnosis and treatment patterns.
  • The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Osteoporosis.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by type - specific cases, comorbidities - related cases, and osteoporotic fracture related cases of Osteoporosis in the 7MM.
Key strengths
  • 10 - Year Forecast of Osteoporosis epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Osteoporosis
  • Prevalent Cases according to segmentation
Key assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: The publisher understands the needs of the rapidly changing market and the publisher is helping the clients by providing them with the most up to date Report. It usually takes 5 - 7 days
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Disease Background and Overview: Osteoporosis
2.1. Introduction
2.2. Types of osteoporosis
2.2.1. Primary osteoporosis
2.2.2. Secondary Osteoporosis
2.2.3. Glucocorticoid-Induced Osteoporosis
2.3. Causes of Osteoporosis
2.4. Symptoms
2.5. Pathophysiology of Osteoporosis
2.5.1. Architectural composition: cortical versus cancellous bone
2.5.2. Molecular composition: mineralized versus nonmineralized components
2.5.3. Cellular control of bone mass: osteoblasts and osteoclasts
2.5.4. Circulating factors that influence bone cell function
2.5.5. Age-related bone loss and osteoporosis
2.5.6. Geometry: effects of osteoporosis on cancellous bone
2.5.7. Geometry: effects of osteoporosis on cortical bone
2.5.8. Geometry: effects on vertebral body strength
2.6. Pathology of Osteoporosis
2.6.1. Factors That Affect Bone Quantity and Quality
2.6.2. Bone Remodeling and its Relationship to Bone Quantity
2.7. Risk Factors for Osteoporosis
2.8. Diagnosis of osteoporosis
2.8.1. Fracture Risk Assessment Tool Model (FRAX)
2.8.2. Vertebral imaging (Vertebral fracture assessment)
2.8.3. Biochemical bone turnover marker (BTM)
2.8.4. Dual-Energy X-Ray Absorptiometry (DXA)
2.8.5. Quantitative Ultrasound (QUS)
2.8.6. Quantitative Computed Tomography (QCT) and Peripheral QCT (pQCT)
2.8.7. Quality of DXA AND VFA
2.9. Diagnostic Biomarkers of Osteoporosis
2.9.1. miR-21 and miR-148a
2.9.2. miR-31 and miR-194
2.9.3. miR-133a and miR-27
2.9.4. miR-30b and miR-142
2.10. Differential diagnosis
2.11. Diagnostic Algorithm
2.12. European Guidelines for diagnosis of Osteoporosis in postmenopausal women
2.12.1. Diagnosis of osteoporosis
2.12.2. Assessment of fracture risk
2.13. Diagnostic guidelines from the Italian Society for Orthopedics and Traumatology
2.13.1. Diagnosis of osteoporosis

3. Recognized Establishments
3.1.1. United States
3.1.2. Europe
3.1.3. Japan

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Countries Total Diagnosed Incident Patient Population of Osteoporosis

5. Country Wise-Epidemiology of Osteoporosis
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Osteoporosis Prevalence in the United States
5.1.3. Osteoporosis Diagnosed Prevalent Population in the United States
5.1.4. Osteoporosis Gender-specific Prevalence in the United States
5.1.5. Primary Osteoporosis Prevalence in the United States
5.1.6. Secondary Osteoporosis Prevalence in the United States
5.1.7. Osteoporotic Fractures Incidence in the United States
5.1.8. Osteoporosis-related comorbidities in the United States
5.2. EU5 Countries
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Germany
5.3.1. Osteoporosis Prevalence in Germany
5.3.2. Osteoporosis Diagnosed Prevalent Population in Germany
5.3.3. Osteoporosis Gender-specific Prevalence in Germany
5.3.4. Primary Osteoporosis Prevalence in Germany
5.3.5. Secondary Osteoporosis Prevalence in Germany
5.3.6. Osteoporotic Fractures Incidence in Germany
5.3.7. Osteoporosis-related comorbidities in Germany
5.4. France
5.4.1. Osteoporosis Prevalence in France
5.4.2. Osteoporosis Diagnosed Prevalent Population in France
5.4.3. Osteoporosis Gender-specific Prevalence in France
5.4.4. Primary Osteoporosis Prevalence in France
5.4.5. Secondary Osteoporosis Prevalence in France
5.4.6. Osteoporotic Fractures Incidence in France
5.4.7. Osteoporosis-related comorbidities in France
5.5. Italy
5.5.1. Osteoporosis Prevalence in Italy
5.5.2. Osteoporosis Diagnosed Prevalent Population in Italy
5.5.3. Osteoporosis Gender-specific Prevalence in Italy
5.5.4. Primary Osteoporosis Prevalence in Italy
5.5.5. Secondary Osteoporosis Prevalence in Italy
5.5.6. Osteoporotic Fractures Incidence in Italy
5.5.7. Osteoporosis-related comorbidities in Italy
5.6. Spain
5.6.1. Osteoporosis Prevalence in Spain
5.6.2. Osteoporosis Diagnosed Prevalent Population in Spain
5.6.3. Osteoporosis Gender-specific Prevalence in Spain
5.6.4. Primary Osteoporosis Prevalence in Spain
5.6.5. Secondary Osteoporosis Prevalence in Spain
5.6.6. Osteoporotic Fractures Incidence in Spain
5.6.7. Osteoporosis-related comorbidities in Spain
5.7. United Kingdom
5.7.1. Osteoporosis Prevalence in the United Kingdom
5.7.2. Osteoporosis Diagnosed Prevalent Population in the United Kingdom
5.7.3. Osteoporosis Gender-specific Prevalence in the United Kingdom
5.7.4. Primary Osteoporosis Prevalence in the United Kingdom
5.7.5. Secondary Osteoporosis Prevalence in the United Kingdom
5.7.6. Osteoporotic Fractures Incidence in the United Kingdom
5.7.7. Osteoporosis-related comorbidities in the United Kingdom
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. Osteoporosis Prevalence in Japan
5.8.3. Osteoporosis Diagnosed Prevalent Population in Japan
5.8.4. Osteoporosis Gender-specific Prevalence in Japan
5.8.5. Primary Osteoporosis Prevalence in Japan
5.8.6. Secondary Osteoporosis Prevalence in Japan
5.8.7. Osteoporotic Fractures Incidence in Japan
5.8.8. Osteoporosis-related comorbidities in Japan

6. Appendix
6.1. Report Methodology

7. Publisher Capabilities

8. Disclaimer

9. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll